Lymphoma News Today

Skip to content
  • Home
  • News Categories
    • Social Clips
    • Hodgkin’s Lymphoma
    • Non-Hodgkin’s Lymphoma
    • Clinical Trial
    • Leukemia & Lymphoma Society
  • About Lymphoma
    • Types Of Lymphoma
      • B-Cell Lymphoma
      • Benign Lymphoma
      • Burkitt’s Lymphoma
      • Cutaneous Lymphoma
      • Follicular Lymphoma
      • Indolent Lymphoma
      • Intestinal Lymphoma
      • Low Grade Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
    • Lymphoma Symptoms
      • Lymphedema
    • Signs Of Lymphoma
    • Lymphoma Diagnosis
    • Lymphoma Prognosis
  • Treatments
    • Approved Treatments
      • CAR T-cell Therapy
        • Kymriah (Tisagenlecleucel)
        • Yescarta (KTE-C19)
      • Adcetris (Brentuximab Vedotin)
      • Aliqopa (Copanlisib)
      • Arzerra (Ofatumumab)
      • Beleodaq (Belinostat)
      • Bendamustine in Lymphomas
      • Besponsa (Inotuzumab Ozogamicin)
      • Calquence (Acalabrutinib)
      • CPX-351
      • Gazyva (Obinutuzumab)
      • Imbruvica (Ibrutinib)
      • Keytruda for Classical Hodgkin Lymphoma (cHL)
      • Rituxan (Rituximab)
      • Rituxan Hycela
      • Revlimid (lenalidomide)
      • Velcade (bortezomib)
      • Venclexta (Venetoclax)
      • Zydelig (Idelalisib)
    • Experimental Treatments
      • ABP798 for Non-Hodgkin’s Lymphoma
      • ADCT-301 in Lymphomas
      • AFM11 for B-Cell Lymphoma
      • AFM13 for Hodgkin’s Lymphoma
      • ALT-803 for Non-Hodgkin Lymphomas
      • Betalutin
      • CMD-003 for Hodgkin’s and non-Hodgkin’s Lymphomas
      • CX-072
      • CPI-818
      • DI-Leu16-IL2
      • Duvelisib
      • GWN323
      • IGN002 for Non-Hodgkin’s Lymphoma
      • Imfinzi (Durvalumab)
      • JCAR017 for B-Cell Non-Hodgkin’s Lymphoma (NHL)
      • JCAR018
      • KTE-X19
      • Mogamulizumab
      • NM-IL-12
      • Oncoquest-L for Follicular Lymphoma
      • OXS-1550
      • PDR001 in Lymphoma
      • Resimmune
      • RG7741 (GDC-0575)
      • Tecentriq (Atezolizumab)
      • TG-1101 (Ublituximab)
      • TGR-1202 (Umbralisib)
      • Xalkori (Crizotinib)
  • Columns
    • Overcoming Adversity
    • Things That Give Me Hope
    • Life After Lymphoma: A Young Warrior’s Guide to Recovery
  • Information About COVID-19

Survivors of Childhood Hodgkin’s Lymphoma Show Increased Likelihood of Cardiovascular Events as Adults

September 8, 2016
Ines Martins, PhDby Ines Martins, PhD

In News.

Survivors of Childhood Hodgkin’s Lymphoma Show Increased Likelihood of Cardiovascular Events as Adults

Click here to subscribe to the Lymphoma News Today Newsletter!

0
(0)

The vast majority of children and adolescents treated for Hodgkin’s lymphoma will survive into adulthood. But according to a recent study developed at St. Jude Children’s Research Hospital, adult survivors of childhood Hodgkin’s lymphoma are more likely to experience cardiovascular events than the general population.

The study, “Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin’s lymphoma: an analysis from the St. Jude Lifetime Cohort Study,” published in The Lancet Oncology, suggests that Hodgkin’s lymphoma survivors will benefit from individualized screening and treatment plans to decrease their risk for cardiovascular events.

Today, nearly 90 percent of patients with pediatric and adolescent Hodgkin’s lymphoma survive into adulthood. But because these patients are treated with chest radiotherapy and anthracyclines, both of which known to increase the risk for cardiovascular disease, survivors may develop severe cardiovascular health disorders, resulting in an increased risk for premature death compared to the general population.

“With cure rates for pediatric cancer at historic highs, the question becomes: What is the legacy of that cure?” Dr. Nickhill Bhakta, MD, hematology-oncology fellow at St. Jude Children’s Research Hospital, said in a press release. “We are doing a better job of keeping patients alive, but are we doing a better job at addressing the chronic diseases that are sometimes the price of that cure?”

In this study, Bhakta and colleagues assessed whether adult Hodgkin’s lymphoma survivors had worse cardiovascular health conditions than general population controls. The researchers applied a new metric, called the cumulative burden method, that quantified the total cardiovascular burden of young survivors by considering all the cardiovascular conditions observed during the patient’s lifetime.

“Cumulative burden is a new tool for studying chronic illness in childhood cancer survivors or any population with significant morbidity, such as diabetes or HIV/AIDS,” Bhakta said.

The study included 670 survivors with a median age at diagnosis of 14.6 years who reached the age of 18 and survived for at least 10 years following the diagnosis of primary Hodgkin’s lymphoma. Data from survivors was obtained from two ongoing cohort studies at St. Jude Children’s Research Hospital.

The St. Jude Lifetime Cohort Study (SJLIFE), which follows health outcomes of childhood cancer survivors treated at the hospital, included data from 348 patients; and the St. Jude Long-term Follow-up Study (SJLTFU), a study initiated in 2000 to collect outcome and late toxicity data for all patients treated at the hospital for childhood cancer, which included 322 Hodgkin’s lymphoma survivors.

All SJLIFE participants were assessed for 22 chronic cardiovascular health conditions, including hypertension, arrhythmias, heart attack, cardiovascular dysfunctions, and structural heart defects, and 272 age and sex frequency-matched SJLIFE community controls were used for comparison.

Results revealed that survivors who reached age 50 were significantly more likely to exhibit severe (grade 3 to grade 5) cardiovascular conditions than healthy controls, with cumulative incidence of 45.5 percent in survivors compared to 15.7 percent in community controls.

The total cumulative burden at age 50 was found to be twice as high, with survivors having 430.6 cardiovascular events in every 100 patients, and community controls having 227.4 events per 100 controls. Cumulative burden for severe events, however, was five times higher than that of community controls (100.8 events per 100 survivors versus 17 events per 100 controls).

The cardiovascular events that contributed the most to the increased cumulative burden in survivors were heart attacks and structural heart defects. In addition, researchers found that although the radiation dose given upon chest radiotherapy influenced the number of severe cardiovascular events, treatment with anthracyclines did not.

“Survivors tended to have more severe disease across the lifespan and likely need an individualized screening and treatment plan,” Bhakta said. “Cumulative burden provides us with a global view of trade-offs between different treatment late effects that must be considered when designing new interventions.”

“Predictions based on the cumulative disease burden might also provide an appropriate method for assessing the socioeconomic cost of progressive chronic heart conditions when evaluating the potential effect of using novel, and hopefully less toxic, cancer treatments,” Marianne C. Aznar, PhD; Sarah Darby, PhD; Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil; and David Cutter, MRCP, FRCR, DPhil, all of the University of Oxford, wrote in an accompanying editorial.

“Prioritizing access to these treatments requires reliable clinical data on their effectiveness and relevant predictions of the future risks they might present (or avoid) to quantify the impact for each individual patient,” they wrote.

  • Author Details
Ines Martins, PhD
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Ines Martins, PhD
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Latest Posts
  • ATG-019 Phase 1 trial
  • ME-401, FDA fast track
  • Tafasitamab combo, lymphoma
  • blood biomarkers
Print Friendly, PDF & EmailPrint This Page

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Tagged anthracyclines, Cardiovascular events, chest radiotherapy, Hodgkin lymphoma, St. Jude Lifetime Cohort Study (SJLIFE), St. Jude Long-term Follow-up Study (SJLTFU).

Post navigation

Previous: 6 Common Myths About Cancer
lymphoma potential therapyNext:Researchers Aim to Spot Markers for Cutaneous Lymphomas That Would Aid Treatment

Recent Posts

  • farewell, honesty, impact, sometimes, superheroes

    A Farewell Note to My Beloved Readers

    February 26, 2021

  • farewell, honesty, impact, sometimes, superheroes

    A Light-giver Shares a Lesson in Emotional Honesty

    February 15, 2021

  • farewell, honesty, impact, sometimes, superheroes

    Embarking on a New Chapter While Cherishing the Value of Community

    February 1, 2021

Featured Posts

FDA Grants Orphan Drug Status to Umbralisib for Follicular Lymphoma

March 19, 2020

Umbralisib orphan drug

The Paradox of Healing

March 9, 2020

grateful, happiness, coronavirus, beauty
Visit Lymphoma News Today's profile on Pinterest.

Lymphoma News Today

BioNews Services, LLC
3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363
  • About Us
  • Our Team
  • Our Guiding Ethics
  • Contact Us
  • Terms of Service
  • Privacy Policy
  • Disable Notifications

Disclaimer:

Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Copyright © 2013-2022 Copyright 2015 © All rights reserved